Skip to main content
. 2022 Oct 19;21:15330338221133640. doi: 10.1177/15330338221133640

Table 5.

Liver Function of Enrolled Patients at Enrollment and After Treatment Discontinuation.

TACE  +  lenvatinib  +  PD-1 inhibitors (n  =  23) TACE  +  lenvatinib (n  =  32) TACE  +  sorafenib (n  =  29) P-value
Elevated ALT
At enrolment 3 (13.04) 3 (9.38) 4 (13.79) .837
After treatment discontinuation 3 (13.04) 5 (15.63) 5 (17.24) .925
P-value 1.000 .708 1.000
Elevated AST
At enrolment 3 (13.04) 4 (12.50) 5 (17.24) 1.000
After treatment discontinuation 6 (26.09) 8 (25.00) 8 (27.59) .728
P value .459 .337 .530

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; RECIST, modified response evaluation criteria in solid tumors; PD-1, programmed death 1; TACE, transarterial chemoembolization.